Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/675,410external-prioritypatent/US9526734B2/en
Application filed by Iceutica Pty LtdfiledCriticalIceutica Pty Ltd
Publication of UY36172ApublicationCriticalpatent/UY36172A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se describen formas de dosis unitarias de meloxicam que contienen 5 mg o 10 mg de meloxicam que proporcionan un eficaz alivio del dolor y tienen propiedades farmacocinéticas deseables. Las formas de dosis unitarias pueden 5 proporcionar alivio del dolor cuando una única dosis unitaria se administra a un paciente y son útiles para tratar el dolor tal como el dolor producido por la osteoartritis con una exposición sistémica al meloxicam relativamente baja.Unit dose forms of meloxicam are described that contain 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties. Unit dose forms can provide pain relief when a single unit dose is administered to a patient and are useful for treating pain such as osteoarthritis pain with a relatively low systemic exposure to meloxicam.
UY0001036172A2015-03-312015-06-17
A NEW FORMULATION OF MELOXICAM
UY36172A
(en)
PROFILACTIC AND / OR THERAPEUTIC AGENT FOR BEHAVIOR AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL ILLNESS CONTAINING BREXPIPRAZOL OR SALTS OF THE SAME